Glecaprevir / Pibrentasvir

Common brands: Mavyret, Neurontin, Gaba 300-Ezs, Gabapentin, Gabarone

Top reporter: Abbvie Inc.

Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]Hepatitis C Virus NS5A Inhibitor [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Platelet Aggregation Inhibitor [EPC]Benzodiazepine [EPC]
10,868
Total Reports
2,035
Serious Reports
287
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (2.64%)

Patient Demographics

Male
5,327
Female
4,735

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Glecaprevir / Pibrentasvir.

# Reaction Reports % of Total
1 FATIGUE 2,563
23.2%
2 HEADACHE 2,204
19.9%
3 NAUSEA 1,132
10.2%
4 PRURITUS 654
5.9%
5 DIARRHOEA 477
4.3%
6 VOMITING 313
2.8%
7 RASH 311
2.8%
8 DIZZINESS 231
2.1%
9 DEATH 224
2.0%
10 PAIN 211
1.9%
11 INSOMNIA 201
1.8%
12 ABDOMINAL DISCOMFORT 197
1.8%
13 DRUG INEFFECTIVE 187
1.7%
14 ASTHENIA 158
1.4%
15 ABDOMINAL PAIN UPPER 149
1.3%
16 DYSPNOEA 147
1.3%
17 THERAPY CESSATION 145
1.3%
18 ABDOMINAL PAIN 142
1.3%
19 CONSTIPATION 139
1.3%
20 ARTHRALGIA 134
1.2%
21 DRUG DOSE OMISSION 131
1.2%
22 PRODUCT DOSE OMISSION 127
1.1%
23 FEELING ABNORMAL 121
1.1%
24 SOMNOLENCE 117
1.1%
25 DECREASED APPETITE 115
1.0%
26 DEPRESSION 112
1.0%
27 PERIPHERAL SWELLING 108
1.0%
28 ANXIETY 107
1.0%
29 HOSPITALISATION 105
0.9%
30 PNEUMONIA 101
0.9%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.